Compare
NeuroSense Therapeutics Ltd. vs Semnur Pharmaceuticals, Inc. vs Provectus Biopharmaceuticals, Inc. vs Alzamend Neuro, Inc.
| Latest fiscal year | NeuroSense Therapeutics Ltd. NRSN | Semnur Pharmaceuticals, Inc. SMNR | Provectus Biopharmaceuticals, Inc. PVCT | Alzamend Neuro, Inc. ALZN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-04-30 |
| Revenue | n/a | n/a | $336.1K | n/a |
| Revenue growth (YoY) | n/a | n/a | -45.5% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/m | n/a |
| Net margin | n/a | n/a | n/m | n/a |
| Net income | -$11.12M | -$160.42M | -$5.43M | -$8.77M |
| EPS (Diluted) | -$0.44 | -$0.78 | -$0.01 | -$2.63 |
| Operating cash flow | -$7.67M | -$5.87M | -$3.33M | -$8.07M |
| Free cash flow | -$7.68M | n/a | n/a | n/a |
| Cash & equivalents | $166.0K | $20.0K | $251.3K | $710.7K |
| Total assets | $1.03M | $1.35M | $697.5K | $2.08M |
| Total liabilities | $2.59M | $22.10M | $7.00M | $1.35M |
| Shareholders' equity | -$1.56M | -$20.75M | -$6.30M | $733.2K |
| Return on year-end equity | n/a | n/a | n/a | n/m |
| Shares outstanding | 32.56M | 230.21M | 420.28M | 4.26M |
Revenue, most recent five fiscal years
| Fiscal year | NeuroSense Therapeutics Ltd. | Semnur Pharmaceuticals, Inc. | Provectus Biopharmaceuticals, Inc. | Alzamend Neuro, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | $336.1K Ended 2025-12-31 | n/a |
| 1 year earlier | n/a | n/a | $617.1K Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | n/a | $557.7K Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | n/a | $989.0K Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | n/a | n/a |